Filing Flows › Artivion (AORT) › Q3 2026
Artivion (AORT) Q3 2026 earnings results (third quarter 2026)
10-Q filed Nov 6, 2026
Artivion (AORT) reported revenue of $124M for the third quarter 2026 (Q3 2026), +9% from a year earlier and -2% from the quarter before. Operating margin was 2.4%, net loss $7.9M (6.4% of revenue).
Artivion, Q3 2026: revenue $124M (+9% year over year), operating margin 2.4%, net loss $7.9M, operating cash flow −$4.6M. The chart follows the revenue to costs, profit and cash.
| Q3 2026 | Amount | Q/Q | Y/Y |
|---|---|---|---|
| Revenue | $124M | -2% | +9% |
| Operating profit | $2.9M | — | -76% |
| Net earnings | −$7.9M | — | -222% |
| Operating cash flow | −$4.6M | — | -120% |
What changed
Revenue was $123.8M in Q3 2026, up 9% year over year and down 2% from the previous quarter. Aortic stent grafts was the largest line at 36% of revenue. Aortic stent grafts added $4.7M year over year (up 12%), 45% of the total change.
Gross margin was 61.4%, down 4.2 points from Q3 2025. Operating profit was $2.9M, a 2.4% margin (down 8.7 points year over year). Operating profit fell $9.6M even though revenue rose $10.4M versus Q3 2025, so costs grew faster than sales. Operating expenses grew 18% against revenue growth of 9%. The quarter ended with a net loss of $7.9M, narrower than the previous quarter's $13.5M loss. Net interest and other expense of $8.9M was the main reason.
Operating cash flow was −$4.6M. Non-cash charges added back $7.3M of depreciation and amortization and $6.2M of share-based compensation. Working capital and other items used $10.2M. Capital expenditures of $13.0M exceeded it, leaving free cash flow of −$17.6M.
Questions
What was Artivion's revenue in the third quarter 2026?
Artivion (AORT) reported revenue of $124M for the third quarter 2026 (Q3 2026), +9% from a year earlier and -2% from the quarter before.
Was Artivion profitable in the third quarter 2026?
Operating profit was $2.9M (2.4% of revenue) and net loss $7.9M.
Source: Artivion 10-Q on SEC EDGAR.